Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,134
  • Shares Outstanding, K 35,067
  • Annual Sales, $ 18,260 K
  • Annual Income, $ -89,760 K
  • 60-Month Beta 1.87
  • Price/Sales 3.78
  • Price/Cash Flow N/A
  • Price/Book 1.80
Trade SPRO with:

Options Overview Details

View History
  • Implied Volatility 133.06% ( +0.86%)
  • Historical Volatility 332.53%
  • IV Percentile 57%
  • IV Rank 8.77%
  • IV High 879.54% on 08/24/22
  • IV Low 61.29% on 12/22/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 515
  • Volume Avg (30-Day) 2,566
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 17,092
  • Open Int (30-Day) 7,305

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.26
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.43
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +62.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.80 +152.50%
on 09/06/22
3.18 -36.48%
on 09/22/22
+1.29 (+177.97%)
since 09/02/22
3-Month
0.68 +197.02%
on 08/02/22
3.18 -36.48%
on 09/22/22
+1.19 (+144.14%)
since 07/01/22
52-Week
0.68 +197.02%
on 08/02/22
18.84 -89.28%
on 10/05/21
-15.53 (-88.49%)
since 10/01/21

Most Recent Stories

More News
Pre-Market Brief: Stocks Mixed as Risk-off Rout Continues

December S&P 500 futures (ESZ22) are trending down -0.17% this morning after three major US benchmark indices ended the previous week at 3-month lows as fears grew that raising interest rates to combat...

ESZ22 : 3,721.25 (+0.84%)
SPRO : 2.02 (+1.00%)
BUD : 45.85 (+1.53%)
RELI : 0.8349 (+7.73%)
SONX : 1.1100 (+3.74%)
ASML : 431.68 (+3.93%)
GOGL : 7.76 (+3.88%)
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

GSK : 30.25 (+2.79%)
PFE : 44.14 (+0.87%)
SPRO : 2.02 (+1.00%)
MORF : 28.14 (-0.57%)
Markets Today: Stocks Extend This Week’s Plunge on Recession Fears

Morning Markets December S&P 500 futures (ESZ22 ) this morning are down by -1.21% at a 2-month low. Stock indexes this morning are extending this week’s sell-off on concern that the Fed’s resolve to...

ESZ22 : 3,721.25 (+0.84%)
COST : 477.73 (+1.16%)
AMD : 66.11 (+4.34%)
FDX : 151.46 (+2.01%)
ACN : 264.89 (+2.95%)
DVN : 65.33 (+8.65%)
FANG : 129.52 (+7.52%)
XOM : 91.92 (+5.28%)
COP : 109.97 (+7.46%)
HAL : 26.38 (+7.15%)
OXY : 64.06 (+4.25%)
MRO : 24.97 (+10.58%)
Pre-Market Brief: Stocks Lower as Post-Fed Stumble Continues

December S&P 500 futures (ESZ22) are trending down -0.58% this morning after three major US benchmark indices ended in the red for a third straight trading session as investors reacted to the Federal Reserve's...

ESZ22 : 3,721.25 (+0.84%)
SPPI : 0.4150 (-3.49%)
COST : 477.73 (+1.16%)
TTOO : 0.1086 (-3.89%)
SPRO : 2.02 (+1.00%)
CANO : 8.96 (+3.34%)
HUM : 499.52 (+2.95%)
CVS : 97.76 (+2.51%)
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr

Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and

SPRO : 2.02 (+1.00%)
GSK : 30.25 (+2.79%)
Micro Cap Up Over +100% In Premarket

A Massachusetts-based %Biotech firm is grabbing the attention of traders across the board during Thursday’s premarket after it was announced that the company has entered into an exclusive license agreement...

GSK : 30.25 (+2.79%)
SPRO : 2.02 (+1.00%)
Pre-Market Brief: Stocks Mixed as Fed Signals More Sharp Rate Hikes

December S&P 500 futures (ESZ22) are trending up +0.49% this morning after three major US benchmark indices jolted up and down before plunging in the final 30 minutes of trading to close Wednesday in the...

ESZ22 : 3,721.25 (+0.84%)
SPRO : 2.02 (+1.00%)
LLY : 321.55 (-0.56%)
CRM : 147.90 (+2.82%)
META : 138.61 (+2.16%)
TCOM : 27.68 (+1.35%)
NVAX : 18.60 (+2.20%)
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More

Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.

NVO : 102.55 (+2.93%)
GILD : 62.32 (+1.02%)
VRTX : 297.43 (+2.73%)
SPRO : 2.02 (+1.00%)
FMTX : 19.95 (unch)
Spero (SPRO) Up Following Positive FDA Update for UTI Drug

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

DVAX : 10.81 (+3.54%)
PFE : 44.14 (+0.87%)
SPRO : 2.02 (+1.00%)
BOLT : 1.5100 (+2.03%)
Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Spero Therapeutics, Inc. (SPRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

SPRO : 2.02 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 2.26
2nd Resistance Point 2.18
1st Resistance Point 2.10
Last Price 2.02
1st Support Level 1.94
2nd Support Level 1.86
3rd Support Level 1.78

See More

52-Week High 18.84
Fibonacci 61.8% 11.90
Fibonacci 50% 9.76
Fibonacci 38.2% 7.62
Last Price 2.02
52-Week Low 0.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar